Concerns raised over the increase in MF in the mouse lymphoma assay were not replicated in vitro in either the Ames study (from a gene mutation mode of action pathway) or in the p53 competent human lymphocyte assay (from a structural chromosomal mode of action pathway). The gene discussed is TP53; the disease is lymphoma.